Spots Global Cancer Trial Database for axicabtagene ciloleucel
Every month we try and update this database with for axicabtagene ciloleucel cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma | NCT05605899 | High-risk Large... | Axicabtagene Ci... Cyclophosphamid... Fludarabine Etoposide Rituximab Doxorubicin Vincristine Prednisone | 18 Years - | Gilead Sciences | |
| Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel | NCT05776160 | Large B-cell Ly... Follicular Lymp... | Axicabtagene Ci... | 18 Years - | Gilead Sciences | |
| Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma | NCT05459571 | Relapsed or Ref... | Axicabtagene Ci... Cyclophosphamid... Fludarabine Dexamethasone | 18 Years - | Gilead Sciences | |
| A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity | NCT04150913 | Non Hodgkin Lym... Refractory Non-... Relapsed Non Ho... Neurotoxicity Neurotoxicity S... Cytokine Releas... | Anakinra Axicabtagene Ci... | 18 Years - | Massachusetts General Hospital | |
| Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | NCT05633615 | Diffuse Large B... Grade 3b Follic... Primary Mediast... Recurrent Diffu... Refractory Diff... Transformed Fol... Transformed Mar... | Axicabtagene Ci... Biospecimen Col... Computed Tomogr... Cyclophosphamid... Fludarabine Lisocabtagene M... Mosunetuzumab Patient Observa... Polatuzumab Ved... Positron Emissi... Tisagenlecleuce... | 18 Years - | SWOG Cancer Research Network | |
| Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma | NCT04432506 | Hematopoietic a... Recurrent Diffu... Recurrent High ... Recurrent Prima... Recurrent Trans... Refractory Diff... Refractory High... Refractory Prim... Refractory Tran... | Anakinra Axicabtagene Ci... Cyclophosphamid... Fludarabine | 18 Years - | M.D. Anderson Cancer Center | |
| Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma | NCT04257578 | B-Cell Non-Hodg... Diffuse Large B... High Grade B-Ce... Primary Mediast... Transformed Fol... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... | Acalabrutinib Axicabtagene Ci... | 18 Years - | University of Washington | |
| Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma | NCT05605899 | High-risk Large... | Axicabtagene Ci... Cyclophosphamid... Fludarabine Etoposide Rituximab Doxorubicin Vincristine Prednisone | 18 Years - | Gilead Sciences | |
| Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma | NCT04205838 | Diffuse Large B... High Grade B-Ce... Progressive Dis... Recurrent Diffu... Recurrent High ... Recurrent Prima... Recurrent Trans... Refractory Diff... Refractory High... Refractory Prim... Refractory Tran... | Anakinra Axicabtagene Ci... Cyclophosphamid... Fludarabine Fludarabine Pho... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy | NCT05075603 | Refractory Diff... Refractory Diff... Recurrent Diffu... Refractory High... Refractory Tran... | Efineptakin alf... Tisagenlecleuce... Axicabtagene ci... Lisocabtagene M... | 18 Years - | NeoImmuneTech | |
| A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma | NCT03105336 | Follicular Lymp... Marginal Zone L... Indolent Non-Ho... | axicabtagene ci... Cyclophosphamid... Fludarabine | 18 Years - | Gilead Sciences | |
| A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma | NCT03105336 | Follicular Lymp... Marginal Zone L... Indolent Non-Ho... | axicabtagene ci... Cyclophosphamid... Fludarabine | 18 Years - | Gilead Sciences | |
| Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy | NCT05075603 | Refractory Diff... Refractory Diff... Recurrent Diffu... Refractory High... Refractory Tran... | Efineptakin alf... Tisagenlecleuce... Axicabtagene ci... Lisocabtagene M... | 18 Years - | NeoImmuneTech | |
| Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma | NCT04205838 | Diffuse Large B... High Grade B-Ce... Progressive Dis... Recurrent Diffu... Recurrent High ... Recurrent Prima... Recurrent Trans... Refractory Diff... Refractory High... Refractory Prim... Refractory Tran... | Anakinra Axicabtagene Ci... Cyclophosphamid... Fludarabine Fludarabine Pho... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma | NCT04205838 | Diffuse Large B... High Grade B-Ce... Progressive Dis... Recurrent Diffu... Recurrent High ... Recurrent Prima... Recurrent Trans... Refractory Diff... Refractory High... Refractory Prim... Refractory Tran... | Anakinra Axicabtagene Ci... Cyclophosphamid... Fludarabine Fludarabine Pho... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma | NCT04002401 | Refractory Larg... | Axicabtagene Ci... Rituximab Fludarabine Cyclophosphamid... | 18 Years - | Gilead Sciences | |
| Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma | NCT04002401 | Refractory Larg... | Axicabtagene Ci... Rituximab Fludarabine Cyclophosphamid... | 18 Years - | Gilead Sciences | |
| Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma | NCT03761056 | B-cell Lymphoma | Axicabtagene Ci... Fludarabine Cyclophosphamid... | 18 Years - | Gilead Sciences | |
| Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma | NCT04432506 | Hematopoietic a... Recurrent Diffu... Recurrent High ... Recurrent Prima... Recurrent Trans... Refractory Diff... Refractory High... Refractory Prim... Refractory Tran... | Anakinra Axicabtagene Ci... Cyclophosphamid... Fludarabine | 18 Years - | M.D. Anderson Cancer Center | |
| Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma | NCT05077527 | AIDS-Related Di... AIDS-Related No... HIV Infection Recurrent Diffu... Recurrent Grade... Recurrent High ... Recurrent Non-H... Recurrent Prima... Recurrent Trans... Refractory Diff... Refractory Grad... Refractory High... Refractory Non-... Refractory Prim... Refractory Tran... | Axicabtagene Ci... Cyclophosphamid... Fludarabine | 18 Years - | AIDS Malignancy Consortium | |
| Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells | NCT05041309 | Solid and Hemat... | Axicabtagene Ci... Brexucabtagene ... KITE-585 KITE-718 KITE-439 KITE-222 KITE-363 | - | Gilead Sciences | |
| Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma | NCT04002401 | Refractory Larg... | Axicabtagene Ci... Rituximab Fludarabine Cyclophosphamid... | 18 Years - | Gilead Sciences | |
| Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma | NCT05459571 | Relapsed or Ref... | Axicabtagene Ci... Cyclophosphamid... Fludarabine Dexamethasone | 18 Years - | Gilead Sciences |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
